LISA RUSSELL: Open Payments
NPI 1093472953 · NEW CASTLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,225 in 174 payments from 20 companies in 2025. Trend: 2023 $2,751 · 2024 $2,960 · 2025 $3,225
Food & beverage: $3,115Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $559 |
| Teva Pharmaceuticals USA, Inc. | 25 | $457 |
| Alkermes, Inc. | 22 | $394 |
| Vanda Pharmaceuticals Inc. | 18 | $370 |
| Otsuka America Pharmaceutical, Inc. | 17 | $281 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $188 |
| Neurocrine BioSciences, Inc. | 8 | $169 |
| Axsome Therapeutics, Inc. | 8 | $145 |
| Sage Therapeutics, LLC | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $93 |
Products named: VRAYLAR, FANAPT, REXULTI, AUSTEDO XR, ARISTADA, CAPLYTA, INGREZZA, LYBALVI.
Industry payments across PA — which companies pay providers there.
